Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBITDA (2016 - 2025)

CytomX Therapeutics' EBITDA history spans 12 years, with the latest figure at -$9.2 million for Q4 2025.

  • For Q4 2025, EBITDA fell 148.59% year-over-year to -$9.2 million; the TTM value through Dec 2025 reached $53000.0, down 99.83%, while the annual FY2025 figure was -$3.6 million, 111.31% down from the prior year.
  • EBITDA reached -$9.2 million in Q4 2025 per CTMX's latest filing, up from -$14.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $23.5 million in Q1 2025 to a low of -$35.1 million in Q4 2021.
  • Average EBITDA over 5 years is -$9.2 million, with a median of -$7.2 million recorded in 2022.
  • The largest YoY upside for EBITDA was 1795.78% in 2024 against a maximum downside of 505.57% in 2024.
  • A 5-year view of EBITDA shows it stood at -$35.1 million in 2021, then skyrocketed by 77.3% to -$8.0 million in 2022, then skyrocketed by 112.48% to $995000.0 in 2023, then soared by 1795.78% to $18.9 million in 2024, then plummeted by 148.59% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for CTMX's EBITDA are -$9.2 million (Q4 2025), -$14.2 million (Q3 2025), and -$120000.0 (Q2 2025).